EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 692 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR Digital Breast Tomosynthesis Found to Detect Invasive Cancers At a Higher... December 8, 2020 High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast... April 23, 2019 ¿Las gammagrafías óseas muestran el cáncer? April 28, 2021 FDA Approves a Fixed-Dose Combination of Nivolumab and Relatlimab for Unresectable... April 12, 2022 Load more HOT NEWS Baby Boy Can’t Stop Smiling After Surgery Allows Him To See... NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared... Foodie Fridays-Gazpacho: A Favorite Summer Soup Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides...
